# SNY — Sanofi · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** SNY  
**Sources:** 29  
**Published:** 2026-10-04  
**Canonical:** https://app.k3vl4r.com/research/deep-research-sny-sanofi-catalysts-narrative-risks-6134

---

# Sanofi (SNY) — Research Notes as of October 4, 2026

*Below is a synthesis of public reporting and analyst data. It is not investment advice.*

## Recent Catalysts (roughly July–October 2026)

**Q2 2026 results and a guidance upgrade.** Sanofi reported Q2 2026 results on/around July 30, 2026, and management subsequently upgraded full-year 2026 guidance, citing double-digit sales growth and double-digit business-earnings-per-share growth driven by pharma launches and Dupixent momentum [[4]](https://www.ad-hoc-news.de/boerse/news/corporate-news/sanofi-stock-steadies-after-strong-q2-2026-and-upgraded-guidance/69978862), [[7]](https://www.benzinga.com/news/26/09/61860657/full-transcript-sanofi-q2-2026-earnings-call), [[9]](https://www.marketbeat.com/stocks/NASDAQ/SNY/earnings/). Management linked the upgrade to "ongoing cost discipline" and a higher-margin product mix [[4]](https://www.ad-hoc-news.de/boerse/news/corporate-news/sanofi-stock-steadies-after-strong-q2-2026-and-upgraded-guidance/69978862).

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-sny-sanofi-catalysts-narrative-risks-6134 (free to sign up)._
